SCHEMBL25146079

SCHEMBL25146079

O=C1NCC2(CN(C(=O)N3CCC4(CC3)CN(Cc3ccc(C(F)(F)F)cc3F)C4)C2)N1

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 2/20 0.43
▸ USP2 O75604 10/20 0.42
▸ CYP2D6 P10635 5/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ HPGD P15428 1/20 0.42
▸ CYP1A2 P05177 3/20 0.42
▸ CYP2C9 P11712 3/20 0.42
▸ CYP2C19 P33261 3/20 0.42
▸ TSHR P16473 3/20 0.41
▸ GPR183 P32249 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ FPR2 P25090 1/20 0.40
▸ ENPP2 Q13822 3/20 0.40
▸ ATXN2 Q99700 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25146247 0.86 FAAH (0.44) FAAHUSP2CYP2D6SMN1; SMN2CYP3A4
SCHEMBL25146080 0.85 MGLL (0.47) FAAHUSP2CYP2D6SMN1; SMN2CYP3A4
SCHEMBL30409293 0.84 FAAH (0.42) FAAHUSP2CYP2D6SMN1; SMN2CYP3A4
SCHEMBL25145595 0.82 MGLL (0.43) FPR2ENPP2ATXN2
SCHEMBL25145621 0.80 FAAH (0.41) FAAHUSP2CYP2D6SMN1; SMN2CYP3A4
SCHEMBL30410099 0.80 MGLL (0.38) FPR2ENPP2ATXN2
SCHEMBL25146284 0.80 ENPP2 (0.42) FAAHUSP2CYP2D6CYP3A4CYP1A2
SCHEMBL30409906 0.80 MGLL (0.41) FAAHUSP2CYP2D6SMN1; SMN2CYP3A4
SCHEMBL23850564 0.80 USP2 (0.53) FAAHUSP2CYP2D6SMN1; SMN2CYP3A4
SCHEMBL25146318 0.79 MGLL (0.46) FAAHGPR183ENPP2ATXN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4416154-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-08-21 — — EP claimed
CN-118103374-A Heterocyclic compounds 豪夫迈·罗氏有限公司 2024-05-28 — — CN claimed
WO-2023062049-A1 HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-04-20 — — WO claimed
US-20240383904-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2024-11-21 — — US disclosed
EP-4416154-A1 HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-08-21 — — EP disclosed
CN-118103374-A Heterocyclic compounds 豪夫迈·罗氏有限公司 2024-05-28 — — CN disclosed
WO-2023062049-A1 HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-04-20 — — WO disclosed
WO-2023062049-A1 HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240383904-A1 HETEROCYCLIC COMPOUNDS MAGI3, MAG, MAGT1 FAAH 54/4885USP2 3142/4885CYP2D6 144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback